Our regulatory science team, led by our Chief Scientific Officer, generates the scientific evidence needed to demonstrate that smoke-free tobacco products result in lower exposure to harmful and potentially harmful constituents and/or are lower risk when compared to conventional cigarettes. We’ve been at the forefront of developing new methodologies to assess the health impact of potentially reduced-risk tobacco products.

We follow a rigorous scientific framework for evaluating potentially reduced-risk tobacco products and supporting product applications to the FDA. This framework enables us to evaluate tobacco products from product design to individual product risk assessments to overall population impact.

Our Regulatory Affairs team applies this rigorous framework to substantiate candidate products demonstrating protection of public health in order to bring new reduced-risk products to adult tobacco consumers.